A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

NCT ID: NCT02963168

Last Updated: 2019-10-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-20
• Study Completion Date: 2020-04-30

Brief Summary

This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.

Detailed Description

This is a multicenter, open-label, safety, tolerability, pharmacokinetic, and activity study. Eligible subjects will be adults with advanced solid malignancies.

Groups of 3 to 6 subjects will receive a single dose of Oradoxel and will be followed for toxicity. If non linearity in PK is observed, additional subjects will receive Oradoxel as 2 single daily doses once every three weeks. Subjects who tolerate the drug and have stable disease or better response will be eligible to receive ongoing treatment.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Oradoxel

To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.

Group Type: EXPERIMENTAL

Oradoxel

Intervention Type: DRUG

oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets

Interventions

Oradoxel

oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets

Intervention Type: DRUG

Other Intervention Names

oral docetaxel + oral HM30181A

Eligibility Criteria

Inclusion Criteria

1. Signed written informed consent

2. ≥18 years of age

3. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

4. Docetaxel monotherapy is a reasonable treatment in the judgement of the Investigator

5. Measurable disease as per RECIST v1.1 criteria

6. Able to swallow oral medication as an intact dosage form

7. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: Absolute neutrophil count (ANC) ≥1500 cells/mm3, Platelet count ≥100 x 109/L, Hemoglobin (Hgb) ≥10 g/dL

8. Adequate liver function as demonstrated by: Total bilirubin of < upper limit of normal (ULN), Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤1.5 × ULN, Alkaline phosphatase (ALP) ≤2.5x ULN or <5x ULN if bone metastases are present, Normal serum albumin

9. Adequate renal function as demonstrated by serum creatinine ≤1.5 x ULN or creatinine clearance>60 mL/min as calculated by the Cockroft and Gault formula

10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

11. Life expectancy of at least 3 months

12. Willing to fast for 6 hours before and 2 hours after Oradoxel administration

13. Females must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or, if sexually active, must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.

14. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

Exclusion Criteria

1. Currently taking a prohibited concomitant medication, other than a premedication, that are/is:

• Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampicin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study)
• Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication ≥1 week before dosing and remain off that medication through the end of PK sampling after the administration of the second study treatment
• An oral medication with a narrow therapeutic index known to be a P-gp substrate within 24 hours prior to start of dosing in the study

2. Unresolved toxicity from prior chemotherapy (subjects must be recovered to ≤ Grade 1 toxicity from previous anticancer treatments or previous investigational products.

3. Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study

4. Received investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longer

5. Require therapeutic use of anticoagulants

6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant myocardial infarction within the last 6 months, unstable angina pectoris, clinically significant cardiac arrhythmia, bleeding disorder, chronic pulmonary disease requiring oxygen, or psychiatric illness/social situations that would limit compliance with study requirements

7. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption

8. A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)

9. Evidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome

10. Any other condition which the Investigator believes would make participation in the study not acceptable

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Athenex, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Cutler, MD

Role: STUDY_DIRECTOR

Athenex, Inc.

Locations

Mayo Clinic

Phoenix, Arizona, United States

Site Status: RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status: RECRUITING

Cancer Therapy & Research Center at UTHSCSA

San Antonio, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

E. Douglas Kramer, MD

Role: CONTACT

dkramer@athenex.com

908-340-6996

Ildiko Bezi

Role: CONTACT

ibezi@athenex.com

908-340-6996

Facility Contacts

Clinical Trials Referral Office

Role: primary

855-776-0015

Clinical Trials Referral Office

Role: primary

855-776-0015

Clinical Trials Office

Role: primary

210-450-1000

Other Identifiers

KX-ORADOX-003

Identifier Type: -

Identifier Source: org_study_id